Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.


BACKGROUND Tyrosine kinase inhibitors (TKIs) such as imatinib mesylate have revolutionized the treatment of primary unresectable and/or metastatic gastrointestinal stromal tumors (GISTs), providing durable disease control and extended survival. Although most patients eventually progress on therapy, dose escalation has been shown to benefit some patients… (More)
DOI: 10.3111/13696998.2010.534670


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics